Given that multiple randomized clinical trials have suggested that postoperative NSCLC patients with a poor prognosis are more likely to benefit from adjuvant therapy (26), the combination of KHK-A and ACSS2 pS659 expression levels can be taken into consideration for decisions regarding the use of adjuvant therapy for NSCLC, especially in the early stage. Here, ACSS2 is linked to non-small cell lung carcinoma.